<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this pilot study we treated <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in patients with <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> to assess intra-arterial fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We analysed effects of intra-arterial infusion on angiographically evident <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in 10 patients including 3 with symptoms of vasospasm </plain></SENT>
<SENT sid="2" pm="."><plain>Over 10 to 30 min 15 to 60 mg was administered via the proximal internal carotid artery or vertebral artery following standard angiography, without superselective techniques </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 24 arterial territories (21 internal carotid, 3 vertebral) were treated </plain></SENT>
<SENT sid="4" pm="."><plain>Angiographic improvement of vasospasm was demonstrated in 16 arterial territories (local dilation in 2, diffuse dilation in 14) in 9 patients </plain></SENT>
<SENT sid="5" pm="."><plain>In 2 symptomatic patients, intra-arterial fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> was associated with resolution of symptoms without sequelae </plain></SENT>
<SENT sid="6" pm="."><plain>In the third symptomatic patient the benefit of fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> was only temporary, and a large <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> occurred </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> asymptomatic patients showed no progression of angiographic to symptomatic vasospasm after treatment with intra-arterial fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>No adverse effect was encountered </plain></SENT>
</text></document>